Audit: QRS - Combining Spirulina, Chlorella, MCP & Modified Alginate Complex for Heavy Metal Detoxification
Audit conducted on 12/09/2026 20:18 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Protocol doses, timing, time-to-effect windows, benefit and risk tiers, all 10 biomarkers and their targets, the cadence and the 6 qualitative markers trace to ER lines 366–370, 427, 173–225, 251–293, 459–479. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Where reported at all” (time_1_sub), “uncontrolled case series” (time_3_sub) and “Small studies without comparison groups” (at_a_glance) carry the ER’s hedging. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay absolute; the disputed systemic-absorption claim is retained as disputed. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | stop_items come from the ER’s “Populations who should avoid” list (ER 333–342), caution_items from the ER interaction bullets (ER 315–331); no Risk-Modifying Factor is promoted into the Risks card. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | None present anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No named investigators, institutions or manufacturers appear. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Reserved, evidence-weighing register matching the ER conclusion. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Doses, windows and target ranges are given plainly so a reader can act; limitations are stated without alarm. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Descriptive throughout; no imperatives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Protocol cells describe what protocols use, not what the reader should do. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “should” or “advised” anywhere. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to those the decision requires; eGFR, ALT and TSH are expanded in the marker names. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate and tier items are reduced to the key fact; no trailing rationale. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed by scan for “you”/”your”: no hits. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Full 10-marker panel, functional ranges and separation windows presuppose an engaged reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Three fasted daily pectin doses plus meal-timed algae are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No simplification of the regimen or the monitoring panel toward mass-market brevity. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance foregrounds the absence of outcome evidence and the funding problem, which is the decision-relevant signal for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” in the file. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Route is given as “all oral” (action_1_sub); “iron tablets” and “digestive upset” are the ER’s own terms (ER 323, 503). |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All twelve headings and both gate headings match the template byte for byte (QRS 440, 477, 519, 574, 593, 723, 539, 554, 597–599). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 22 distinct template variable names present, with marker_#/qualitative_item_# expanded to 10 and 6 numbered instances. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Normalised diff against the template shows differences only inside variable spans and the metadata block; the three website="…" spans, the style block and all structural markup are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Standard regimen”, “Timing relative to each other”, “Best time of day” match ER 366/368/370; interaction labels match ER 315–331. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names reproduce the ER biomarker column exactly, including the “(eGFR)”, “(ALT)” and “(TSH)” expansions. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | The ER’s tier emoji and the ⚠️/⭕️ markers are stripped; tiers are bold text on CSS-coloured cards. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every optional element is condensed to the key fact; the only long blocks are the 10 biomarker rows and 6 qualitative markers that items 14.2 and 15.2 require in full. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Comment opens at line 2, immediately after the doctype at line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in the header or footer. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, which the colon requires. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4 matches the ER file on disk. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.9.11, matching the QRS.md badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0912-1953. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version only; no context or tier qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9 matches the file’s own name. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Title reproduces the ER canonical_topic with & encoding plus the required suffix. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417 matches ER frontmatter line 8, & encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | 2026-0912-1953 → 09/12/2026. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | “Opus 5”, matching the metadata. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only title and the template subline; the ER’s “Also known as” line is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Compresses all four conclusion paragraphs (ER 499–505): compartments, evidence quality, risks, funding. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | Counted at exactly 60 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Four agents/three gut-acting (ER 499), no combination trial and no outcome benefit (ER 501), digestive upset and contamination (ER 503), seller funding (ER 505). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “comparison groups” replaces “controlled”, “partly absorbed” replaces “systemic”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers other than the count of agents. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from the “Populations who should avoid” list at ER 333–342 inside that section. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-list entries are present; the absolute spirulina/immunosuppressant contraindication (ER 321) is covered by “immunosuppressant therapy”. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements, QRS 542–549. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | ER rationale clauses (“where safety is unestablished…”, “given documented microcystin…”, “where prescription chelation is…”) are all stripped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | CKD staging and the < 30 mL/min/1.73 m² threshold, the under-18 age cut and the mould cross-reactivity qualifier are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in these bullets. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names eight such populations and the section is correspondingly populated. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map to the interaction bullets at ER 315–331. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eight of the nine ER bullets carried; the immunosuppressant bullet is correctly omitted because it appears in [stop_items]. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements, QRS 557–564. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER mitigation clause and mechanism sentence is dropped; only the label plus its drug list survives. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All named drug lists are kept, the antacid/bismuth/iron examples are recovered from the ER body, and “in anticoagulated people only” is preserved on the vitamin K item. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation in these bullets. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names nine interactions and the section is correspondingly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells map to ER 366, 368 and 370 in Therapeutic Protocol. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, mutual timing and time of day are the three executable variables; the remaining ER bullets are comparative or explanatory. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine variables carry ER-derived content; doses, the 2:1 ratio and the two-hour separation are reproduced exactly. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Symptom change, urinary output and blood/hair concentration are the only three windows the ER gives (ER 427). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Symptom change (Medium-tier arsenic skin lesions) leads, followed by the two Low-tier excretion and burden endpoints. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct aspects exist; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | 16 weeks, 24 hours to 6 days and 4 to 12 weeks all match ER 427, with the ER’s hedges carried into the sub-lines. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect data, so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All eight items are the ER’s own benefit headings from ER 173–225. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present and populated at the correct tiers. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; the ER’s Magnitude paragraphs, mmHg figures and confidence intervals are absent. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any benefits item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry at least one ER benefit. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All seven items are the ER’s own risk headings from ER 251–293. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present and populated at the correct tiers. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Headings only; the microcystin percentages, pheophorbide-a mechanism and case-report detail are omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in any risks item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry at least one ER risk. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows reproduce the ER biomarker table at ER 459–470. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 10 ER biomarkers present in ER order, with the Optimal Functional Range and “Why Measure It?” columns carried verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Reproduces the baseline, 4- and 12-week, 6-to-12-month and 2-week clotting recheck schedule from ER 457. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Taken from the qualitative marker list at ER 472–479. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers present, verbatim and in ER order. |
Issues 12/09/2026 20:18
Pass rate 100.00%. No issues found.
Issues 12/09/2026 20:12
- 7.4 — Technical term in lede: The At-A-Glance opens with “Four food-derived binders”, using “binders” as a bare technical category noun that a non-specialist would not recognise; the ER Conclusion itself uses the self-explanatory “binding agents”.
Fixes 12/09/2026 20:12
- 7.4 — Technical term in lede: Replaced “Four food-derived binders” with “Four food-derived binding agents” in the At-A-Glance span, adopting the ER Conclusion’s own self-explanatory wording; the lede remains within the 60-word limit.
Issues 12/09/2026 20:06
- 1.3 — Pectin not identified as modified: [action_1_value] at line 447 reads “15 g pectin”, broadening the ER’s “15 g modified citrus pectin” (ER line 366); the ER’s Sourcing section (ER line 410) states that ordinary citrus pectin does not share the active structure and was never tested.
Fixes 12/09/2026 20:06
- 1.3 — Pectin identified as modified: [action_1_value] changed from “15 g pectin” to “15 g MCP”, and [action_1_sub] now opens with “Modified citrus pectin (MCP);” so the dose is tied to the tested low-molecular-weight product rather than ordinary citrus pectin.
Issues 12/09/2026 20:00
- 8.4 — Drug list added to contraindication: The contraindication “Active autoimmune disease, or immunosuppressant therapy” (line 544) carries a parenthetical drug list that the ER’s avoid-population bullet does not contain; it was imported from the separate Key Interactions bullet and is an elaboration rather than a qualifier preserved under 8.5.
Fixes 12/09/2026 20:00
- 8.4 — Drug list stripped from contraindication: Changed the contraindication on line 544 from “Active autoimmune disease, or immunosuppressant therapy (ciclosporin, tacrolimus, azathioprine, mycophenolate)” to “Active autoimmune disease, or immunosuppressant therapy”, matching the ER’s avoid-population bullet.